ACURX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.25 USD | +4.17% |
|
+10.84% | -41.25% |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to Acurx Pharmaceutical...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
Calendar
2024-06-17
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.25
USD
Average target price
11.45
USD
Spread / Average Target
+408.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.25% | 35.6M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Transcript : Acurx Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 2022